Edition:
United States

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

43.59USD
12:39pm EDT
Change (% chg)

$0.47 (+1.09%)
Prev Close
$43.12
Open
$43.35
Day's High
$43.62
Day's Low
$43.04
Volume
1,725,894
Avg. Vol
6,248,281
52-wk High
$45.81
52-wk Low
$33.20

Select another date:
Photo

FDA approves Pfizer's drug for advanced breast cancer

The U.S. Food and Drug Administration said on Tuesday it approved Pfizer Inc's drug for an advanced form of breast cancer tied to an inherited gene mutation.

UPDATE 1-FDA approves Pfizer's drug for advanced breast cancer

Oct 16 The U.S. Food and Drug Administration said https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm623540.htm?utm_campaign=Oncology%2010%2F16%2F18%20talazoparib&utm_medium=email&utm_source=Eloqua&elqTrackId=3d45c5bae09748aa82b26d0d48f2c15b&elq=98e4248d80d04ab2907cce369a7c5176&elqaid=5513&elqat=1&elqCampaignId=4429 on Tuesday it approved Pfizer Inc's drug for an advanced form of breast cancer tied to an inherited gene mutation.

FDA approves Pfizer's breast cancer drug

Oct 16 The U.S. Food and Drug Administration said https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm623540.htm?utm_campaign=Oncology%2010%2F16%2F18%20talazoparib&utm_medium=email&utm_source=Eloqua&elqTrackId=3d45c5bae09748aa82b26d0d48f2c15b&elq=98e4248d80d04ab2907cce369a7c5176&elqaid=5513&elqat=1&elqCampaignId=4429 on Tuesday it approved Pfizer Inc's drug for advanced form of breast cancer.

Pfizer hit with multi-plaintiff suit over anti-seizure drug Dilantin

Pfizer Inc has been sued by 10 people alleging the company and its subsidiaries failed to warn of the risk of severe brain damage from its anti-seizure medication Dilantin.

U.S. Supreme Court declines antitrust case against Pfizer over Lipitor

The U.S. Supreme Court on Tuesday declined to review the dismissal of a lawsuit involving a group of California pharmacists who allege Pfizer Inc conspired with Ranbaxy Laboratories Ltd to delay sales of generic versions of its cholesterol drug Lipitor.

Pfizer to replace longtime CEO Read with veteran Bourla

Pfizer Inc Chief Executive Officer Ian Read will hand over the reins of the largest U.S. drugmaker to veteran insider Albert Bourla in January, after eight years at the helm, in the backdrop of increased scrutiny over drug pricing.

UPDATE 6-Pfizer to replace longtime CEO Read with veteran Bourla

* Pfizer shares have risen 160 pct during Read's tenure (Adds background on Read and Bourla; updates shares)

Pfizer CEO to step down

Oct 1 Pfizer Inc said on Monday its Chief Executive Officer Ian Read would step down at the start of next year.

Pfizer's lung cancer drug gets FDA approval

Pfizer Inc said on Thursday that its once-daily oral drug to treat a rare form of lung cancer received approval from the U.S. Food and Drug Administration.

UPDATE 1-Pfizer's lung cancer drug gets FDA approval

Sept 27 Pfizer Inc said on Thursday that its once-daily oral drug to treat a rare form of lung cancer received approval from the U.S. Food and Drug Administration.

Select another date: